Subject: Possible intro to friend at cancer nano technology company
From: "Andrew Herscowitz" <[email-masked]>
To: <[email-masked]>
Date: Mon, 18 Jan 2016 09:05:30 +0200

Hunter,

Happy New Year!  Do you have any interest in meeting Mitch?  He's a great
guy and was a partner I worked with at Piper. He then brought me to
Brobeck.  He's a very loyal friend, as well. He gave up law firm life when
his brother Gary died of cancer at 39, leaving behind young kids. Mitch
decided to work full time for a company in Rockville called Cytimmune that
focuses on the use of nano technology to fight cancer.  It's supposedly
cutting edge stuff.  I'm not sure how involved you are or are going to be
in your dad's anti-cancer effort, but if you are going to be involved,
would you want to meet Mitch?  If not, no big deal.  I suspect that you
wouldn't get into the weeds on something like this, but Mitch is really
smart, down-to-earth and committed.

I'll be in DC next week for just a week.  We're launching Power Africa's
"Roadmap" at a White House event on Monday morning (Jan. 25), and then
we'll have a reception at the Blair House on Tuesday (Jan. 26).  Let me
know if you'd want to stop by either event. It would be great to see you.

Andy

---------- Forwarded message ----------
From: Mitchell Marder <[email-masked]>
Date: Sun, Jan 17, 2016 at 8:56 PM
Subject: Hello
To: "Herscowitz, Andrew" <[email-masked]>

Andy,

Hammer tells me that he spoke with you recently. Hope all is well and
staying safe. Crazy stuff in Kenya – I assume that S.A. is relatively calm
even though you have travel throughout the area.

I need  your help. I am sure that you heard POTUS' so-called "moonshot" for
cancer under the leadership of the VP. The call is for cures within the
next 5 years. In brief, this will not happen with the same old approach of
throwing it at basic research, relying on the usual academic suspects, and
building more infrastructure. I believe that the best chance is to  to get
funding to mid-stage companies with drugs in the clinic with leaps in
approach, not incremental approaches, to treat people. These companies
 don't have the needed funds to complete trials given the expense and
current economic environment; so timing is key.

As you may know, CytImmune is one of those companies. We have major
hospitals and scientists at NIH supporting our technology but the gap in
funding is with the private sector and the current climate. Keep in mind
that government has not traditionally funded later stage clinical trials
because it is viewed as commercialization/product development – something
traditionally left to the private sector not government. I hope this will
finally change now under Joe's leadership! The current system has not
worked. I truly believe that our drug might have helped Beau just like it
might have helped my brother had it been available.

Sorry for the soap box. I am hoping that we might be able to get a brief
audience with the VP. I recall that you are friendly with Hunter from
college. Please see what you can do. We have trials ready to go in NYC,
Barcelona and Paris at major cancer centers where they are picking up the
patient cost (highly unusual – a real validation from the science
community). We just need funds to complete manufacture of next lot of drug
and related expenses.

As one of the leaders in our field of cancer, the NCI (National Cancer
Institute at NIH) asked Larry to write an article – I thought you might
find it interesting. I hope that you can help. Larry's son Eric, who met
you in Pretoria, is now at Homeland and he is a privacy liaison with the
WhiteHouse. Eric is also trying to help get our story in front of the VP.

Best,
Mitchell

Mitchell S. Marder
Executive Vice President, Corporate Development &
Chief Legal Officer
CytImmune Sciences, Inc.
15010 Broschart Road
Rockville, Maryland 20850
+301 825-3041 (Tel)
+202 415-4928 (Mobile)
[email-masked]

CONFIDENTIALITY NOTICE

The information in this message (and associated attachments, if any) is
confidential and may be legally privileged. It is intended solely for the
addressee(s). Access to this message by anyone other than the addressee is
unauthorized. If you are not the intended recipient, any disclosure,
copying, distribution or other action taken,  is prohibited and may be
unlawful. If you have received this message in error, please notify the
sender immediately and delete all electronic copies of this message (and
associated attachments). Destroy any hard copies you may have created